Annals of medicine and surgery (2012)
FDA expanded approval of Pluvicto (Lutetium-177 vipivotide tetraxetan) in metastatic castration-sensitive prostate cancer.
Malakia Saqib, Bilal Arshad, Sakan Binte Imran, Ehtisham Haider
Published: 202610.1097/MS9.0000000000004548
No abstract available for this study.